Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-434
NCT02862457Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of epacadostat in solid tumor and non-small cell lung cancer (NSCLC) (7 cohorts), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities, Adverse Events up to 39.7 months and 1 more. Started Aug 2016; status: completed.
02
Drugs
epacadostat
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02862457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862457.